- Home
- NWTN vs ACRS Comparison
NWTN vs ACRS Comparison
Compare NWTN & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NWTN
- ACRS
- Stock Information
- Founded
- NWTN 2016
- ACRS 2012
- Country
- NWTN United Arab Emirates
- ACRS United States
- Employees
- NWTN N/A
- ACRS N/A
- Industry
- NWTN Auto Manufacturing
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- NWTN Consumer Discretionary
- ACRS Health Care
- Exchange
- NWTN Nasdaq
- ACRS Nasdaq
- Market Cap
- NWTN 115.1M
- ACRS 127.6M
- IPO Year
- NWTN N/A
- ACRS 2015
- Fundamental
- Price
- NWTN $0.42
- ACRS $1.14
- Analyst Decision
- NWTN
- ACRS Strong Buy
- Analyst Count
- NWTN 0
- ACRS 7
- Target Price
- NWTN N/A
- ACRS $11.67
- AVG Volume (30 Days)
- NWTN 1.2M
- ACRS 968.2K
- Earning Date
- NWTN 01-01-0001
- ACRS 05-06-2025
- Dividend Yield
- NWTN N/A
- ACRS N/A
- EPS Growth
- NWTN N/A
- ACRS N/A
- EPS
- NWTN N/A
- ACRS N/A
- Revenue
- NWTN $583,000.00
- ACRS $18,720,000.00
- Revenue This Year
- NWTN N/A
- ACRS N/A
- Revenue Next Year
- NWTN N/A
- ACRS $425.96
- P/E Ratio
- NWTN N/A
- ACRS N/A
- Revenue Growth
- NWTN N/A
- ACRS N/A
- 52 Week Low
- NWTN $0.30
- ACRS $0.95
- 52 Week High
- NWTN $7.49
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- NWTN 48.68
- ACRS 27.21
- Support Level
- NWTN $0.35
- ACRS $1.05
- Resistance Level
- NWTN $0.43
- ACRS $1.23
- Average True Range (ATR)
- NWTN 0.07
- ACRS 0.11
- MACD
- NWTN 0.01
- ACRS -0.01
- Stochastic Oscillator
- NWTN 37.66
- ACRS 16.82
About NWTN NWTN Inc.
NWTN Inc is a pioneering smart electric vehicle company which aims to integrate avant-garde design, life-style personalization, IoT connectivity, and autonomous driving technology into a passenger-centric green premium mobility solution to the world.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.